Merck and Kelun-Biotech’s sacituzumab tirumotecan (sac-TMT) plus Keytruda reduced the risk of disease progression or death by 65% versus Keytruda alone in a phase 3 OptiTROP-Lung05 abstract released ahead of ASCO 2026. The dataset, drawn from treatment-naïve, PD-L1–positive NSCLC patients in China, adds a new frontline standard-of-care challenge for antibody-drug conjugate–immunotherapy combinations.